These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 7777869)
1. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer. Kotz KW; Schilder RJ Semin Oncol; 1995 Jun; 22(3):250-62. PubMed ID: 7777869 [No Abstract] [Full Text] [Related]
2. High dose chemotherapy with cisplatin, VP16 and carboplatin with stem cell support in patients with advanced ovarian cancer. Pierelli L; Menichella G; Foddai ML; Serafini R; Vittori M; Paoloni A; Benedetti Panici P; Scambia G; Baiocchi G; Greggi S Haematologica; 1991 Mar; 76 Suppl 1():63-5. PubMed ID: 1677915 [TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer. Cure H; Legros M; Fleury J; Dauplat J; Condat P; Choufi B; Chollet P; Plagne R Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S34-5. PubMed ID: 8899168 [No Abstract] [Full Text] [Related]
4. [High-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis]. Hayakawa S; Sato S; Yajima A Gan To Kagaku Ryoho; 1995 Oct; 22(12):1756-61. PubMed ID: 7574806 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380 [TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166 [No Abstract] [Full Text] [Related]
7. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer]. Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398 [TBL] [Abstract][Full Text] [Related]
8. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Murakami M; Shinozuka T; Kuroshima Y; Tokuda Y; Tajima T Semin Oncol; 1994 Feb; 21(1 Suppl 1):29-32. PubMed ID: 8153654 [No Abstract] [Full Text] [Related]
10. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952 [TBL] [Abstract][Full Text] [Related]
11. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332 [TBL] [Abstract][Full Text] [Related]
12. [Is still there an indication for high-dose chemotherapy with hematopoietic stem-cell support in the treatment of germ-cell tumors?]. Fléchon A; Droz JP Bull Cancer; 2001 Sep; 88(9):852-7. PubMed ID: 11604357 [TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous bone marrow support in ovarian carcinoma: the bottom line, more or less. Thigpen T Gynecol Oncol; 1995 Jun; 57(3):275-7. PubMed ID: 7774829 [No Abstract] [Full Text] [Related]
14. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646 [TBL] [Abstract][Full Text] [Related]
16. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Peters WP; Ross M; Vredenburgh JJ; Hussein A; Rubin P; Dukelow K; Cavanaugh C; Beauvais R; Kasprzak S Semin Oncol; 1994 Aug; 21(4 Suppl 7):25-31. PubMed ID: 7916487 [TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS; Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126 [TBL] [Abstract][Full Text] [Related]
18. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406 [TBL] [Abstract][Full Text] [Related]
19. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. Morgan MA; Stadtmauer EA; Luger SM; Porter DL; Mangan PA; O'Neil P; Kamelle S; Benjamin I; Mick R; King SA; Rubin SC Gynecol Oncol; 1997 Dec; 67(3):272-6. PubMed ID: 9441774 [TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors of ovarian cancer]. Ochiai K Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]